Datapoint: BMS-Turning Point Deal Could Shake Up Lung Cancer Market

Bristol Myers Squibb last week entered a deal to acquire Turning Point Therapeutics, the clinical-state oncology company that’s currently developing a promising kinase inhibitor for non-small cell lung cancer (NSCLC) and advanced solid tumors. The drug, repotrectinib, targets ROS1 and NTRK gene mutations, and has seen solid trial results that could make it a major rival to Roche’s Rozlytrek. As a treatment for NSCLC, Rozlytrek currently holds covered or better status for 97% of all insured lives under the pharmacy benefit. 41.1% of insured lives have preferred access to Rozlytrek, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/6/22

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today